Recent submissions

  • Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD. 

    Hewitt, G; Borel, V; Segura-Bayona, S; Takaki, T; Ruis, P; Bellelli, R; Lehmann, LC; Sommerova, L; Vancevska, A; Tomas-Loba, A; Zhu, K; Cooper, C; Fugger, K; Patel, H; Goldstone, R; Schneider-Luftman, D; Herbert, E; Stamp, G; Brough, R; Pettitt, S; Lord, CJ; West, SC; Ahel, I; Ahel, D; Chapman, JR; Deindl, S; Boulton, SJ (2020-12-15)
    Chromatin is a barrier to efficient DNA repair, as it hinders access and processing of certain DNA lesions. ALC1/CHD1L is a nucleosome-remodeling enzyme that responds to DNA damage, but its precise function in DNA repair ...
  • Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. 

    Piscuoglio, S; Ng, CKY; Geyer, FC; Burke, KA; Cowell, CF; Martelotto, LG; Natrajan, R; Popova, T; Maher, CA; Lim, RS; Bruijn, ID; Mariani, O; Norton, L; Vincent-Salomon, A; Weigelt, B; Reis-Filho, JS
    Metaplastic breast cancer (MBC) is a rare special histologic type of triple-negative breast cancer, characterized by the presence of neoplastic cells showing differentiation towards squamous epithelium and/or mesenchymal ...
  • CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. 

    Johnson, N; Maguire, S; Morra, A; Kapoor, PM; Tomczyk, K; Jones, ME; Schoemaker, MJ; Gilham, C; Bolla, MK; Wang, Q; Dennis, J; Ahearn, TU; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Arndt, V; Aronson, KJ; Augustinsson, A; Baynes, C; Freeman, LEB; Beckmann, MW; Benitez, J; Bermisheva, M; Blomqvist, C; Boeckx, B; Bogdanova, NV; Bojesen, SE; Brauch, H; Brenner, H; Burwinkel, B; Campa, D; Canzian, F; Castelao, JE; Chanock, SJ; Chenevix-Trench, G; Clarke, CL; NBCS Collaborators; Conroy, DM; Couch, FJ; Cox, A; Cross, SS; Czene, K; Dörk, T; Eliassen, AH; Engel, C; Evans, DG; Fasching, PA; Figueroa, J; Floris, G; Flyger, H; Gago-Dominguez, M; Gapstur, SM; García-Closas, M; Gaudet, MM; Giles, GG; Goldberg, MS; González-Neira, A; AOCS Group; Guénel, P; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hamann, U; Harrington, PA; Hart, SN; Hooning, MJ; Hopper, JL; Howell, A; Hunter, DJ; ABCTB Investigators; kConFab Investigators; Jager, A; Jakubowska, A; John, EM; Kaaks, R; Keeman, R; Khusnutdinova, E; Kitahara, CM; Kosma, V-M; Koutros, S; Kraft, P; Kristensen, VN; Kurian, AW; Lambrechts, D; Le Marchand, L; Linet, M; Lubiński, J; Mannermaa, A; Manoukian, S; Margolin, S; Martens, JWM; Mavroudis, D; Mayes, R; Meindl, A; Milne, RL; Neuhausen, SL; Nevanlinna, H; Newman, WG; Nielsen, SF; Nordestgaard, BG; Obi, N; Olshan, AF; Olson, JE; Olsson, H; Orban, E; Park-Simon, T-W; Peterlongo, P; Plaseska-Karanfilska, D; Pylkäs, K; Rennert, G; Rennert, HS; Ruddy, KJ; Saloustros, E; Sandler, DP; Sawyer, EJ; Schmutzler, RK; Scott, C; Shu, X-O; Simard, J; Smichkoska, S; Sohn, C; Southey, MC; Spinelli, JJ; Stone, J; Tamimi, RM; Taylor, JA; Tollenaar, RAEM; Tomlinson, I; Troester, MA; Truong, T; Vachon, CM; van Veen, EM; Wang, SS; Weinberg, CR; Wendt, C; Wildiers, H; Winqvist, R; Wolk, A; Zheng, W; Ziogas, A; Dunning, AM; Pharoah, PDP; Easton, DF; Howie, AF; Peto, J; Dos-Santos-Silva, I; Swerdlow, AJ; Chang-Claude, J; Schmidt, MK; Orr, N; Fletcher, O (2021-01-26)
    BACKGROUND: Epidemiological studies provide strong evidence for a role of endogenous sex hormones in the aetiology of breast cancer. The aim of this analysis was to identify genetic variants that are associated with urinary ...
  • Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK-A16037) 

    Banerjee, S; Tovey, H; Bowen, R; Folkerd, E; Kilburn, L; McLachlan, J; Hall, M; Tunariu, N; Attygalle, A; Lima, JPDSN; Perry, S; Chatfield, P; Hills, M; Kaye, S; Attard, G; Dowsett, M; Bliss, JM (SAGE PUBLICATIONS LTD, 2020-12-01)
  • Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers. 

    Glubb, DM; Thompson, DJ; Aben, KK; Alsulimani, A; Amant, F; Annibali, D; Attia, J; Barricarte, A; Beckmann, MW; Berchuck, A; Bermisheva, M; Bernardini, MQ; Bischof, K; Bjørge, L; Bodelon, C; Brand, AH; Brenton, JD; Brinton, LA; Bruinsma, F; Buchanan, DD; Burghaus, S; Bützow, R; Cai, H; Carney, ME; Chanock, SJ; Chen, C; Chen, X; Chen, Z; Cook, LS; Cunningham, JM; De Vivo, I; DeFazio, A; Doherty, JA; Dork, T; du Bois, A; Dunning, AM; Durst, M; Edwards, T; Edwards, RP; Ekici, AB; Ewing, A; Fasching, PA; Ferguson, S; Flanagan, JM; Fostira, F; Fountzilas, G; Friedenreich, CM; Gao, B; Gaudet, MM; Gawełko, J; Gentry-Maharaj, A; Giles, GG; Glasspool, R; Goodman, MT; Gronwald, J; Harris, HR; Harter, P; Hein, A; Heitz, F; Hildebrandt, MAT; Hillemanns, P; Høgdall, E; Høgdall, CK; Holliday, EG; Huntsman, DG; Huzarski, T; Jakubowska, A; Jensen, A; Jones, ME; Karlan, BY; Karnezis, A; Kelley, JL; Khusnutdinova, E; Killeen, JL; Kjaer, SK; Klapdor, R; Köbel, M; Konopka, B; Konstantopoulou, I; Kopperud, RK; Koti, M; Kraft, P; Kupryjanczyk, J; Lambrechts, D; Larson, MC; Le Marchand, L; Lele, S; Lester, J; Li, AJ; Liang, D; Liebrich, C; Lipworth, L; Lissowska, J; Lu, L; Lu, KH; Macciotta, A; Mattiello, A; May, T; McAlpine, JN; McGuire, V; McNeish, IA; Menon, U; Modugno, F; Moysich, KB; Nevanlinna, H; Odunsi, K; Olsson, H; Orsulic, S; Osorio, A; Palli, D; Park-Simon, T-W; Pearce, CL; Pejovic, T; Permuth, JB; Podgorska, A; Ramus, SJ; Rebbeck, TR; Riggan, MJ; Risch, HA; Rothstein, JH; Runnebaum, IB; Scott, RJ; Sellers, TA; Senz, J; Setiawan, VW; Siddiqui, N; Sieh, W; Spiewankiewicz, B; Sutphen, R; Swerdlow, AJ; Szafron, LM; Teo, SH; Thompson, PJ; Thomsen, LCV; Titus, L; Tone, A; Tumino, R; Turman, C; Vanderstichele, A; Velez Edwards, D; Vergote, I; Vierkant, RA; Wang, Z; Wang-Gohrke, S; Webb, PM; White, E; Whittemore, AS; Winham, SJ; Wu, X; Wu, AH; Yannoukakos, D; Spurdle, AB; O'Mara, TA (2020-11-03)
    BACKGROUND:Accumulating evidence suggests a relationship between endometrial cancer and ovarian cancer. Independent genome-wide association studies (GWAS) for endometrial cancer and ovarian cancer have identified 16 and ...
  • Primidone blocks RIPK1-driven cell death and inflammation. 

    Riebeling, T; Jamal, K; Wilson, R; Kolbrink, B; von Samson-Himmelstjerna, FA; Moerke, C; Ramos Garcia, L; Dahlke, E; Michels, F; Lühder, F; Schunk, D; Doldi, P; Tyczynski, B; Kribben, A; Flüh, C; Theilig, F; Kunzendorf, U; Meier, P; Krautwald, S (2020-12-03)
    The receptor-interacting serine/threonine protein kinase 1 (RIPK1) is a key mediator of regulated cell death and inflammation. Recent studies suggest that RIPK1 inhibition would fundamentally improve the therapy of ...
  • Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. 

    Martin, M; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Turner, N; Ciruelos, EM; Muñoz, M; Bermejo, B; Margeli, M; Anton, A; Kahan, Z; Csöszi, T; Casas, MI; Murillo, L; Morales, S; Alba, E; Gal-Yam, E; Guerrero-Zotano, A; Calvo, L; Haba-Rodriguez, JDL; Ramos, M; Alvarez, I; Garcia-Palomo, A; Bartlett, CH; Koehler, M; Caballero, R; Corsaro, M; Huang, X; Garcia-Sáenz, JA; Chacón, JI; Swift, C; Thallinger, C; Gil-Gil, M (2020-12-29)
    <h4>Background</h4>Palbociclib plus endocrine therapy (ET) is the standard treatment for hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer (MBC). However, its efficacy ...
  • IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis. 

    Siersbæk, R; Scabia, V; Nagarajan, S; Chernukhin, I; Papachristou, EK; Broome, R; Johnston, SJ; Joosten, SEP; Green, AR; Kumar, S; Jones, J; Omarjee, S; Alvarez-Fernandez, R; Glont, S; Aitken, SJ; Kishore, K; Cheeseman, D; Rakha, EA; D'Santos, C; Zwart, W; Russell, A; Brisken, C; Carroll, JS (2020-09)
    The cytokine interleukin-6 (IL6) and its downstream effector STAT3 constitute a key oncogenic pathway, which has been thought to be functionally connected to estrogen receptor α (ER) in breast cancer. We demonstrate that ...
  • Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. 

    Smith, I; Robertson, J; Kilburn, L; Wilcox, M; Evans, A; Holcombe, C; Horgan, K; Kirwan, C; Mallon, E; Sibbering, M; Skene, A; Vidya, R; Cheang, M; Banerji, J; Morden, J; Sidhu, K; Dodson, A; Bliss, JM; Dowsett, M (2020-11)
    <h4>Background</h4>Preoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer. It has also been suggested ...
  • Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. 

    Finn, RS; Cristofanilli, M; Ettl, J; Gelmon, KA; Colleoni, M; Giorgetti, C; Gauthier, E; Liu, Y; Lu, DR; Zhang, Z; Bartlett, CH; Slamon, DJ; Turner, NC; Rugo, HS (2020-11)
    <h4>Purpose</h4>This analysis evaluated the relationship between treatment-free interval (TFI, in PALOMA-2)/disease-free interval (DFI, in PALOMA-3) and progression-free survival (PFS) and overall survival (OS, in PALOMA-3), ...
  • PIK3CA mutation enrichment and quantitation from blood and tissue. 

    Keraite, I; Alvarez-Garcia, V; Garcia-Murillas, I; Beaney, M; Turner, NC; Bartos, C; Oikonomidou, O; Kersaudy-Kerhoas, M; Leslie, NR (2020-10-13)
    PIK3CA is one of the two most frequently mutated genes in breast cancers, occurring in 30-40% of cases. Four frequent 'hotspot' PIK3CA mutations (E542K, E545K, H1047R and H1047L) account for 80-90% of all PIK3CA mutations ...
  • EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. 

    Smyth, EC; Vlachogiannis, G; Hedayat, S; Harbery, A; Hulkki-Wilson, S; Salati, M; Kouvelakis, K; Fernandez-Mateos, J; Cresswell, GD; Fontana, E; Seidlitz, T; Peckitt, C; Hahne, JC; Lampis, A; Begum, R; Watkins, D; Rao, S; Starling, N; Waddell, T; Okines, A; Crosby, T; Mansoor, W; Wadsley, J; Middleton, G; Fassan, M; Wotherspoon, A; Braconi, C; Chau, I; Vivanco, I; Sottoriva, A; Stange, DE; Cunningham, D; Valeri, N (2020-11-16)
    <h4>Objective</h4>Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between ...
  • Molecular Drivers of Onco<i>type</i> DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. 

    Buus, R; Sestak, I; Kronenwett, R; Ferree, S; Schnabel, CA; Baehner, FL; Mallon, EA; Cuzick, J; Dowsett, M (2021-01)
    <h4>Purpose</h4>The Onco<i>type</i> DX Recurrence Score (RS), Prosigna Prediction Analysis of Microarray 50 (PAM50) Risk of Recurrence (ROR), EndoPredict (EP), and Breast Cancer Index (BCI) are used clinically for estimating ...
  • 90 YEARS OF PROGESTERONE: Progesterone receptor signaling in the normal breast and its implications for cancer. 

    Brisken, C; Scabia, V (2020-07)
    Progesterone is considered as the pregnancy hormone and acts on many different target tissues. Progesterone receptor (PR) signaling is important for normal development and the physiologic function of the breast and impinges ...
  • A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer Medicine. 

    Nyamundanda, G; Eason, K; Guinney, J; Lord, CJ; Sadanandam, A (2020-09-30)
    One of the major challenges in defining clinically-relevant and less heterogeneous tumor subtypes is assigning biological and/or clinical interpretations to etiological (intrinsic) subtypes. Conventional clustering/subtyping ...
  • Sox9 regulates cell state and activity of embryonic mouse mammary progenitor cells. 

    Kogata, N; Bland, P; Tsang, M; Oliemuller, E; Lowe, A; Howard, BA (2018-12-13)
    Embryonic mammary cells are a unique population comprised of undifferentiated, highly plastic progenitor cells that create normal mammary tissues. The mammary gland continues to develop after birth from descendants of ...
  • Do we still need breast cancer screening in the era of targeted therapies and precision medicine? 

    Trimboli, RM; Giorgi Rossi, P; Battisti, NML; Cozzi, A; Magni, V; Zanardo, M; Sardanelli, F (2020-09-25)
    Breast cancer (BC) is the most common female cancer and the second cause of death among women worldwide. The 5-year relative survival rate recently improved up to 90% due to increased population coverage and women's ...
  • Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline <i>PTEN</i> Mutations. 

    Kingston, B; Bailleux, C; Delaloge, S; Schiavon, G; Scott, V; Lacroix-Triki, M; Carr, TH; Kozarewa, I; Gevensleben, H; Kemp, Z; Pearson, A; Turner, N; André, F (2019-01)
  • Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. 

    Pascual, J; Lim, JSJ; Macpherson, IR; Armstrong, AC; Ring, A; Okines, AFC; Cutts, RJ; Herrera-Abreu, MT; Garcia-Murillas, I; Pearson, A; Hrebien, S; Gevensleben, H; Proszek, PZ; Hubank, M; Hills, M; King, J; Parmar, M; Prout, T; Finneran, L; Malia, J; Swales, KE; Ruddle, R; Raynaud, FI; Turner, A; Hall, E; Yap, TA; Lopez, JS; Turner, NC (2020-09-21)
    Cyclin-dependent kinase 4/6 (CDK4/6) and PI3K inhibitors synergize in <i>PIK3CA</i>-mutant ER-positive HER2-negative breast cancer models. We conducted a phase Ib trial investigating the safety and efficacy of doublet ...

View more